HomeCompareMDGEF vs BTI

MDGEF vs BTI: Dividend Comparison 2026

MDGEF yields 77.22% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MDGEF wins by $1.43M in total portfolio value
10 years
MDGEF
MDGEF
● Live price
77.22%
Share price
$2.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.46M
Annual income
$412,841.82
Full MDGEF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — MDGEF vs BTI

📍 MDGEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDGEFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDGEF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDGEF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDGEF
Annual income on $10K today (after 15% tax)
$6,563.71/yr
After 10yr DRIP, annual income (after tax)
$350,915.55/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, MDGEF beats the other by $348,546.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDGEF + BTI for your $10,000?

MDGEF: 50%BTI: 50%
100% BTI50/50100% MDGEF
Portfolio after 10yr
$751.1K
Annual income
$207,814.23/yr
Blended yield
27.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

MDGEF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-23.8
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDGEF buys
0
BTI buys
0
No recent congressional trades found for MDGEF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDGEFBTI
Forward yield77.22%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$1.46M$37.7K
Annual income after 10y$412,841.82$2,786.64
Total dividends collected$1.27M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: MDGEF vs BTI ($10,000, DRIP)

YearMDGEF PortfolioMDGEF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$18,422$7,722.01$11,299$598.92+$7.1KMDGEF
2$33,006$13,294.85$12,794$703.91+$20.2KMDGEF
3$57,579$22,261.83$14,518$829.07+$43.1KMDGEF
4$97,904$36,294.48$16,513$978.64+$81.4KMDGEF
5$162,433$57,675.85$18,827$1,157.84+$143.6KMDGEF
6$263,233$89,430.36$21,518$1,373.12+$241.7KMDGEF
7$417,107$135,446.75$24,657$1,632.46+$392.4KMDGEF
8$646,885$200,581.45$28,329$1,945.74+$618.6KMDGEF
9$982,896$290,728.34$32,637$2,325.33+$950.3KMDGEF
10$1,464,540$412,841.82$37,708$2,786.64+$1.43MMDGEF

MDGEF vs BTI: Complete Analysis 2026

MDGEFStock

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Full MDGEF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this MDGEF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDGEF vs SCHDMDGEF vs JEPIMDGEF vs OMDGEF vs KOMDGEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.